Pirfenidone Clinical Trials
8 recruitingDrug
Phase 24Phase 33Phase 11Not Applicable1
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)250 enrolled1 locationNCT03109288
Recruiting
Not Applicable
Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Assiut University1,000 enrolled2 locationsNCT05842681
Recruiting
Phase 3
Pirfenidone to Prevent Fibrosis in Ards.
Acute Respiratory Distress Syndrome (ARDS)
Università Vita-Salute San Raffaele130 enrolled17 locationsNCT05075161
Recruiting
Phase 2
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim20 enrolled3 locationsNCT06241560
Recruiting
Phase 3
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Idiopathic Pulmonary Fibrosis (IPF)
Sunshine Lake Pharma Co., Ltd.472 enrolled1 locationNCT07082842
Recruiting
Phase 3
Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
Long COVID
Douglas D. Fraser348 enrolled9 locationsNCT06928272
Recruiting
Phase 2
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
Recurrent Acute Pancreatitis
University of Alabama at Birmingham60 enrolled2 locationsNCT06253117
Recruiting
Phase 2
Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors
Lung Cancer
Hubei Cancer Hospital41 enrolled1 locationNCT05801133